UNITED GUARDIAN INC - 10-Q Summary (Q1 2011)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2011. United-Guardian, Inc. is a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The company operates primarily from its facility in Hauppauge, New York, and markets products globally through distributors and marketing partners.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Net Sales | $3,642,049 | $3,576,915 |
| Net Income | $1,166,183 | $1,095,844 |
| Earnings Per Share (Basic/Diluted) | $0.25 | $0.22 |
| Operating Margin | 45.6% | 43.2% |
| Net Cash from Operating Activities | $1,423,064 | $953,986 |
| Cash and Cash Equivalents | $2,563,637 | $2,216,474 |
| Working Capital | $12,990,379 | $11,765,995 |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 1.8% ($65,134) compared to Q1 2010. This was driven by a 15.0% increase in personal care product sales, largely due to higher volume from the largest distributor. However, pharmaceutical sales dropped 63.2% due to a temporary production curtailment of the key product RENACIDIN.
- Profitability: Net income rose 6.4% to $1.17 million. Operating expenses decreased 15.7% due to lower payroll, consulting fees, and a real estate tax refund.
- Liquidity: Cash and cash equivalents increased by $1.05 million. Working capital improved by $1.22 million. The current ratio decreased from 12.5 to 1 to 9.6 to 1, primarily due to higher accounts payable and income taxes payable.
- Investment Income: Decreased 22.7% to $71,323 due to lower interest rates and investment balances.
Outlook, Risks, and Unusual Items
- Product Supply Risk: The significant decline in pharmaceutical sales was caused by a supplier curtailment of RENACIDIN production. The supplier resumed production in March 2011, and the company expects to resume normal sales by mid-May 2011.
- Dividends: No dividends were paid in Q1 2011. The company paid a dividend of $1.58 million in Q1 2010. Management intends to continue using cash for dividends and marketable securities.
- Unusual Items: The company recorded a $5,253 loss on the sale of a company vehicle to a Vice President as part of a severance package.
- Guidance: Management believes working capital is sufficient for the next 12 months and does not expect significant capital expenditures for the remainder of 2011. The effective tax rate is expected to remain consistent at approximately 33%.
Investor Verification Checklist
- Verify the timeline for the full resumption of RENACIDIN sales and the impact on Q2 2011 pharmaceutical revenue.
- Confirm the stability of the largest distributor's demand for personal care products following the Q1 inventory replenishment.
- Review the composition of marketable securities ($8.68 million) and the impact of interest rate fluctuations on future investment income.
- Monitor the company's cash deployment strategy regarding future dividend payments versus share buybacks or acquisitions.